|
1
|
Fallah HH, Zareei MA, Ziai SA, et al: The
effects of Taraxacum officinale L. and Berberis
vulgaris L. root extracts on carbon tetrachloride induced liver
toxicity in rats. J Med Plants. 9:45–52. 2010.
|
|
2
|
Hermenean A, Popescu C, Ardelean A, Stan
M, Hadaruga N, Mihali CV, Costache M and Dinischiotu A:
Hepatoprotective effects of Berberis vulgaris L. extract/β
cyclodextrin on carbon tetrachloride-induced acute toxicity in
mice. Int J Mol Sci. 13:9014–9034. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weber LW, Boll M and Stampfl A:
Hepatotoxicity and mechanism of action of haloalkanes: Carbon
tetrachloride as a toxicological model. Crit Rev Toxicol.
33:105–136. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ruch RJ, Klaunig JE, Schultz NE, Askari
AB, Lacher DA, Pereira MA and Goldblatt PJ: Mechanism of
chlorophorm and carbon tetrachloride toxicity in primary cultured
mouse hepatocytes. Environ Health Perspect. 69:301–305. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Videla LA: Oxidative stress signaling
underlying liver disease and hepatoprotective mechanisms. World J
Hepatol. 1:72–78. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Balahoroğlu R, Dülger H, Özbek H and
Bayram I Şekeroğlu: Protective effects of antioxidants on the
experimental liver and kidney toxicity in mice. Eur J Gen Med.
5:157–164. 2008.
|
|
7
|
Manibusan MK, Odin M and Eastmond DA:
Postulated carbon tetrachloride mode of action: A review. J Environ
Sci Health C Environ Carcinog Ecotoxicol Rev. 25:185–109. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Arayne MS, Sultana N and Bahadur SS: The
Berberis story: Berberis vulgaris in therapeutics. Pak J
Pharm Sci. 20:83–92. 2007.PubMed/NCBI
|
|
9
|
Ivanovska N and Philipov S: Study on the
anti-inflamatory action of Berberis vulgaris root extract,
alkaloid fractions and pure alkaloids. Int J Immunopharmacol.
18:553–561. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Singh A, Duggal S, Kaur N and Singh J:
Berberine. Alkaloid with wide spectrum of pharmacological
activities. J Nat Prod (Gorakhpur). 3:64–75. 2010.
|
|
11
|
Freile ML, Giannini F, Pucci G, Sturniolo
A, Rodero L, Pucci O, Balzareti V and Enriz RD: Antimicrobial
activity of aqueous extracts and of berberine isolates from
Berberis heterophylla. Fitoterapia. 74:702–705. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iizuka N, Miyamoto K, Okita K, Tangoku A,
Hayashi H, Yosino S, Abe T, Morioka T, Hazama S and Oka M:
Inhibitory effect of Coptidis rhizoma and berberine on the
proliferation of human esophageal cancer cell lines. Cancer Lett.
148:19–25. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuo CL, Chi CW and Liu TY: The
anti-inflamatory potential of berberine in vitro and in vivo.
Cancer Lett. 203:127–137. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kupeli E, Koşar M, Yeşilada E, Hüsnü K and
Başer C: A comparative study on the anti-inflamatory,
antinociceptive and antipyretic effects of isoquinoline alkaloids
from the root of turkish Berberis species. Life Sci.
72:645–657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Feng Y, Siu KY, Ye X, Wang N, Yuen MF,
Leung CH, Tong Y and Kobayashi S: Hepatoprotective effects of
berberine on carbon tetrachloride-induced acute hepatotoxicity in
rats. Chin Med. 5:332010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rasheed A, Kumanr A and Sravahthi V:
Cyclodextrins as drug carrier molecule: A review. Sci Pharm.
76:567–598. 2008. View Article : Google Scholar
|
|
17
|
Guo L, Dial S, Shi L, Branham W, Liu J,
Fang JL, Green B, Deng H, Kaput J and Ning B: Similarities and
differences in the expression of drug-metabolizing enzymes between
human hepatic cell lines and primary human hepatocytes. Drug Metab
Dispos. 39:528–538. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Imanshahidi M and Hosseinzadeh H:
Pharmacological and therapeutical effects of Berberis
vulgaris and its active constituent, berberine. Phytother Res.
22:999–1012. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang BJ, Xu D, Guo Y, Ping J, Chen LB and
Wang H: Protection by and anti-oxidant mechanism of berberine
against rat liver fibrosis induced by multiple hepatotoxic factors.
Clin Exp Pharmacol Physiol. 35:303–309. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fukuda K, Hibiya Y, Mutoh M, Koshiji M,
Akao S and Fujiwara H: Inhibition of berberine of cyclooxygenase-2
transcriptional activity in human colon cancer cells. J
Ethnopharmacol. 66:227–233. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Meng Z, Li T, Ma X, Wang X, Van Ness C,
Gan Y, Zhou H, Tang J, Lou G, Wang Y, et al: Berbamine inhibits the
growth of liver cancer cells and cancer-initiating cells by
targeting Ca2+/calmodulin-dependent protein kinase II.
Mol Cancer Ther. 12:2067–2077. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma S, Wang Y, Shang X, et al: Formulation
of berberine hydrochloride and hydroxypropyl-β-cyclodextrin
inclusion complex with enhanced dissolution and reduced bitterness.
Trop J Pharm Res. 11:871–877. 2012.
|
|
23
|
Ziolkowski W, Szkatula M, Nurczyk A,
Wakabayashi T, Kaczor JJ, Olek RA, Knap N, Antosiewicz J,
Wieckowski MR and Wozniak M: Methyl-beta-cyclodextrin induces
mitochondrial cholesterol depletion and alters the mitochondrial
structure and bioenergetics. FEBS Lett. 584:4606–4610. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kiss T, Fenyvesi F, Bácskay I, Váradi J,
Fenyvesi E, Iványi R, Szente L, Tósaki A and Vecsernyés M:
Evaluation of the cytotoxicity of β-cyclodextrin derivatives:
Evidences for the role of cholesterol extraction. Eur J Pharm Sci.
40:376–380. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kamel HH, Azza HA, Walaa MSA and Amira HM:
Protective effect of some antioxidants against
CCl4-induced toxicity in liver cells from BRL3A cell
line. J Am Sci. 6:992–993. 2010.
|
|
26
|
Guo XL, Liang B, Wang XW, Fan FG, Jin J,
Lan R, Yang JH, Wang XC, Jin L and Cao Q: Glycyrrhizic acid
attenuates CCl4-induced hepatocyte apoptosis in rats via
a p53-mediated pathway. World J Gastroenterol. 19:3781–3791. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen J, Tao X, Li L, Sun A, Wang Y and
Zhang S: Protective effect of blueberry anthocyanins in a
CCl4-induced injury model in human embryonic liver
cells. Food Agric Immunol. 25:274–286. 2013. View Article : Google Scholar
|
|
28
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Saelens X, Festjens N, Van de Walle L, van
Gurp M, van Loo G and Vandenabeele P: Toxic proteins released from
mitochondria in cell death. Oncogene. 23:2861–2874. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saraste A and Pulkki K: Morphological and
biomedical hallmarks of apoptosis. Cardiovasc Res. 45:528–537.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aydin HH, Celik A, Deveci R, Karacali S,
Saydam G, Omay Bedii S and Batur Y: Induction of apoptosis by fatty
acid ethyl esters in HepG2 cells. Food Chem Toxicol. 43:139–145.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bao W, Pan H, Lu M, Ni Y, Zhang R and Gong
X: The apoptotic effect of sarsasapogenin from Anemarrhena
asphodeloides on HepG2 human hepatoma cells. Cell Biol Int.
31:887–892. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fujimoto Y, Itabe H, Kinoshita T, Homma
KJ, Onoduka J, Mori M, Yamaguchi S, Makita M, Higashi Y, Yamashita
A and Takano T: Involvement of ACSL in local synthesis of neutral
lipids in cytoplasmic lipid droplets in human hepatocyte HuH7. J
Lipid Res. 48:1280–1292. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Peyrou M, Ramadori P, Bourgoin L and Foti
M: PPARs in liver diseases and cancer: Epigenetic regulation by
microRNAs. PPAR Res. 2012:7578032012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rakic B, Sagan SM, Noestheden M, Bélanger
S, Nan X, Evans CL, Xie XS and Pezacki JP: Peroxisome
proliferator-activated receptor alpha antagonism inhibits hepatitis
C virus replication. Chem Biol. 13:23–30. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Toyoda M, Takagi H, Horiguchi N, Kakizaki
S, Sato K, Takayama H and Mori M: A ligand for peroxisome
proliferator activated receptor gamma inhibits cell growth and
induces apoptosis in human liver cancer cells. Gut. 50:563–567.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Morán-Salvador E, Titos E, Rius B,
González-Périz A, García-Alonso V, López-Vicario C, Miquel R, Barak
Y, Arroyo V and Clària J: Cell-specific PPARγ deficiency
establishes anti-inflamatory and anti-fibrogenic properties for
this nuclear receptor in non-parenchimal liver cells. J Hepatol.
59:1045–1053. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Orfila C, Lepert JC, Alric L, Carrera G,
Béraud M and Pipy B: Immunohistochemical distribution of nuclear
factor kappaB and peroxisome proliferated-activated receptors in
carbon tetrachloride- induced chronic liver injury in rats.
Histochem Cell Biol. 123:585–593. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu JS, Lin TN and Wu KK: Rosiglitazone and
PPAR-gamma overexpression protect mitochondrial membrane potential
and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family
proteins. J Cell Physiol. 220:58–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
